BAY-218 NEW
| Price | $34 | $46 | $66 |
| Package | 1mg | 2mg | 5mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-11 |
Product Details
| Product Name: BAY-218 | CAS No.: 2162982-11-6 |
| Purity: 99.95% | Supply Ability: 10g |
| Release date: 2026/06/11 |
Product Introduction
Bioactivity
| Name | BAY-218 |
| Description | BAY-218 is an aryl hydrocarbon receptor (AHR) antagonist with IC50 of 39.9 nM in the human glioblastoma U87 cell line. BAY-218 inhibition of AhR stimulates pro-inflammatory monocyte and T cell responses in vitro and drives anti-tumor immune responses, leading to reduced tumor growth in vivo. |
| In vitro | METHODS: Human monocytic U937 cells were treated with BAY-218 (AHR antagonist 1)(1 nM, 3nM, 10nM, 30nM, 100nM, 300nM, 1 μΜ and 3μΜ) and the IC50 values were determined. RESULTS BAY-218 exhibited CYP1A1 inhibitory activity with an IC50 of 70.7 μM in the human monocytic U937 cell line. [1] METHODS: BAY-218 (72 pM, 0.25 nM, 0.89 nM; 3.1 nM, 1 1 nM, 38 nM, 130 nM, 470 nM, 1.6 pM, 5.7 p, 20 μM) was used to treat U87 glioblastoma cells endogenously expressing AHR and the IC50 value was determined. RESULTS BAY-218 could inhibit the activity of AHR in U87 glioblastoma cells with an IC50 of 39.9 μM. [1] |
| In vivo | METHODS: BAY-218 (30 mg/kg, oral, twice daily) and aPD-L1 (10 mg/kg, intraperitoneal injection, twice daily) were used to treat mice with CT26 tumor cell xenografts injected subcutaneously in the flank to observe their anti-tumor ability. RESULTS Combination therapy of BAY-218 and aPD-L1 inhibited tumor growth in mice. [1] |
| Storage | Store at low temperature,Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 252 mg/mL (627.15 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween-80+45% Saline : 3.3 mg/mL (8.21 mM), Sonication is recommended. |
| Keywords | U87 glioblastoma cells | Inhibitor | inhibit | immune | human monocytic U937 cells | cancer | BAY-218 | BAY218 | BAY 218 | ArylHydrocarbonReceptor | aryl hydrocarbon receptor (AHR) | Aryl Hydrocarbon Receptor | AHR antagonist-1 | AHR antagonist1 | AhR |
| Inhibitors Related | Nimodipine | Diosmin | Sudan IV | 2-Mercaptobenzothiazole | Benzyl butyl phthalate | 1-Hydroxypyrene | Skatole | Tryptamine hydrochloride | L-Kynurenine | Indole-3-carbinol | Leflunomide | Dibenzothiophene |
| Related Compound Libraries | Nonsteroidal Anti-Inflammatory Compound Library | Bioactive Compound Library | Multi-Target Compound Library | Inhibitor Library | NO PAINS Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Transcription Factor-Targeted Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1980.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
| $2800.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-21 | |
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-26 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY